marrow does not develop myeloid hypoplasia, during a nadir in the WBC as noted in the previously reported cases with cyclic oscillation.
The Philadelphia chromosome-negative myeloproliferative diseases (MPD) are a group of late-onset, chronic haematopoietic disorders characterized by the clonal proliferation of stem and progenitor cells resulting in an increased output of mature cells of one or more blood cell lineages. A specific acquired mutation in the key haematopoietic kinase, Janus kinase-2 (JAK2), JAK2V617F, occurs within the regulatory pseudokinase JAK homology-2 (JH2) domain of the JAK2 molecule and is proposed to result in release of autoinhibition of the JAK homology-1 (JH1) kinase domain. This lesion, which occurs in exon 14 of JAK2, is associated with 495% of polycythaemia vera (PV) cases and approximately 50% of patients diagnosed with essential thrombocythaemia (ET) and idiopathic myelofibrosis (IMF), (reviewed by Kaushansky 2007) . 1 The JAK2V617F mutation arises in the stem cell compartment consistent with the clonal proliferation of a multipotent progenitor that maintains longterm clonal haematopoiesis. 2 Further, the identification of a mutation in a kinase that is associated with multiple cytokine receptors (CR) is consistent with altered growth factor responses observed in PV. For example, the growth of erythropoietin (Epo)-independent 'endogenous' erythroid colonies (eBFUE) from bone marrow (BM) and peripheral blood (PB) samples in vitro is a key feature of PV and ET and can be utilized as a diagnostic tool.
Further somatic mutations have been reported in JAK2V617F-negative MPD patients, including a transmembrane mutation in Mpl (Thrombopoietin receptor) in a small proportion of IMF and ET patients, 3 and more recently, a cluster of four different mutations in exon 12 of JAK2 has been described in JAK2V617F-negative PV and idiopathic erythrocytosis patients. 4, 5 This group of mutations, affecting amino-acid residues F537-E543, lies in a highly conserved region proximal to the JH2 domain of JAK2 and results in altered growth factor responses in vitro and a myeloproliferative phenotype in a murine bone marrow transplant model. 4 Through a network of clinical haematologists in South Australia, we have obtained written informed consent (Royal Adelaide Hospital Research Ethics Approval #991104a), PB and/ or BM samples, and clinical information from a cohort of 62 patients, all of whom presented with unexplained erythrocytosis. We have screened peripheral blood mononuclear cell (PBMNC) or bone marrow mononuclear cell (BMMNC) samples from the majority of patients for the presence of eBFUE, and from all patients for the presence of the JAK2V617F mutation. We initially used PCR amplification and sequencing of JAK2 exon 14 in individually isolated eBFUE as described. 6 Subsequently, we screened for the mutation in PBMNC, BMMNC and/ or eBFUE patient samples using a sensitive allele-specific PCR technique (AS-PCR) 6 or the single-nucleotide primer-extension genotyping assay system, iPLEX t (Sequenom, San Diego, CA, USA). Using these approaches, we have shown in all 62 patients with erythrocytosis either the presence of eBFUE (n ¼ 40) or the JAK2V617F mutation (n ¼ 59) or both, in agreement with the recently proposed World Health Organization revised criteria for the diagnosis of PV. 7 We detected the JAK2V617F allele in 59 out of 62 patients (95.16%), consistent with reported frequencies of JAK2V617F in PV, where sensitive detection methods have been employed. 6 Three female patients (PV31, PV63 and PV64) were positive for eBFUE formation from PBMNC or BMMNC samples, confirming PV diagnosis. However, all three patients were negative for the JAK2V617F mutation measured using direct PCR amplification and sequencing of JAK2 exon 14 from individual eBFUE (PV31 n ¼ 7; PV63 n ¼ 1), and PBMNC (PV31 and PV63) or BMMNC (PV64) samples (determined by JAK2V617F AS-PCR or iPLEX assay, data not shown). Further to the report of four somatic inframe deletions or tandem point mutations in exon 12 of JAK2 in patients with JAK2V617F-negative PV or idiopathic erythrocytosis, 4 we screened genomic DNA from individual eBFUE isolated from patients PV31, PV63 and PV64, and control samples, for mutations in this exon using a PCR-based sequencing approach (forward primer: CTCCTCTTTGGAG CAATTCA; reverse primer: TATCGCAACTCCCTTGTTCTC;
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annealing temperature 57 1C). Mutations were not detected in JAK2 exon 12 in the JAK2V617F-positive human erythroleukaemia (HEL) cell line, BFUE isolated from two normal individuals or in eBFUE isolated from four PV patients harbouring the JAK2V617F mutation (data not shown). However, a novel, complex exonic deletion was detected as a recurrent heterozygous change in 5/5 individual eBFUE isolated from each of the patients PV31 and PV63. Cloning of JAK2 exon 12 PCR products derived from PV31 and PV63 eBFUE revealed two separate deletions of two base pairs and four base pairs in close proximity on the same allele in both patients (Figure 1 ). This maintains the reading frame of JAK2 beyond the affected sequence, resulting in the deletion of 4 amino-acid residues from 540 to 543 inclusive (I540-E543) and the insertion of 2 amino acids, methionine and lysine (JAK2I540-E543delinsMK) (Figure 2) . Further sequence analysis of PV31 and PV63 PCR products confirmed that the mutation detected in both patients was not due to contamination between samples since a homozygous 5 bp (tctta) deletion within intron 12 sequence (178 bp downstream from the exon/intron boundary) was detected in PV63 eBFUE but was not present in PV31 eBFUE. This deletion is likely to represent a normal variant as it was also detected in BFUE isolated from a normal individual and from eBFUE isolated from 4 JAK2V617F-positive PV patients (data not shown). Sequencing of PCR products derived from patient PV64 revealed a second novel heterozygous JAK2 exon 12 deletion in one eBFUE isolated from a BM sample taken 2.5 years after PV diagnosis. Cloning of PCR products demonstrated a 6 base-pair deletion (Figure 1 ) resulting in the loss of 3 amino-acid residues from 541 to 543 inclusive (R541-E543) and insertion of a single amino acid, lysine (JAK2R541-E543delinsK) in this patient (Figure 2) .
The JAK2I540-E543delinsMK and JAK2R541-E543delinsK mutations represent novel JAK2 mutations in the region defined by Scott et al. 4 Alignment with the previously reported JAK2 exon 12 mutations demonstrates a number of mutations affecting a region of seven highly conserved amino acids (F537-E543) predicted to lie between the Src homology 2 (SH2)-like motif and the JH2 domain of JAK2 (Figure 2 ). Taken together with data presented by Scott et al., 4 our findings are consistent with a highly specific cluster of activating mutations occurring in JAK2 exon 12 in the majority of PV patients lacking the JAK2V617F mutation. We predict that the functional consequences of the JAK2I540-E543delinsMK and JAK2R541-E543delinsK mutations will be similar to that described for other mutations in this region. 4 The JAK2I540-E543delinsMK and JAK2R541-E543delinsK mutations were not readily detectable by direct sequencing of PCR products amplified from PV31 PBMNC or PV64 BMMNC samples, respectively, suggesting that the number of cells bearing the mutation in these cell populations are below the limit of detection by sequencing and are consistent with the presence of an acquired alteration in the eBFUE population in these patients. However, the JAK2I540-E543delinsMK mutation was readily detected in PCR product amplified from patient PV63 PBMNC, at a level comparable to eBFUE (Figure 1) . There are several possible explanations for this finding. In this patient, the eBFUE as well as the mature monocyte and lymphocyte populations may be carrying the heterozygous change leading to full penetration of the disease clone in all haematopoietic lineages, as previously reported in a small number of JAK2V617F-positive MPD patients. 8 In support of this, early BM pathology obtained three years before PV diagnosis suggests that PV63 may have had long-standing disease, allowing time for full clonal haematopoiesis to have occurred (see below). Additional mutational events in this patient may be associated with amplification of additional cellular compartments. ). eBFUE were scored after 12-14 days culture at 37 1C, 5% CO 2 using standard microscopic morphological criteria. 
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Alternatively, although not previously reported in patients with JAK2 exon 12 mutations, the patient may have a proportion of cells in the PBMNC population in which both alleles are mutated. While we have detected an identical JAK2 mutation in two patients (PV31 and PV63) and a similar mutation in patient PV64, disease presentation and progression varied considerably between the patients (Table 1 ). PV31 presented with mildly elevated haemoglobin (Hgb) at an early age (32 years). The average age of diagnosis of JAK2V617F-positive patients in our cohort is 63.05711.85 years, range 40-84 years (n ¼ 40). Bone marrow cytogenetic analysis was normal, although the marrow was hypercellular with mild dysplastic changes of the megakaryocytes. Thromboembolic complications or other evidence of progressive disease remained absent in this patient 4 years after PV diagnosis. Patient PV63 had pre-existing chronic obstructive lung disease and presented at age 84 years with markedly elevated haemoglobin. The patient was started on regular venesections but developed deep-vein thrombosis (DVT) after 2 months. Of note, platelet levels were increasing during this time (from 310 to 618 Â 10 9 l
À1
), although the patient developed iron deficiency, presumably due to the phlebotomy therapy. Hydroxyurea and warfarin anticoagulation therapy resolved the DVT and blood counts normalized upon cessation of venesections, however the patient died as a result of respiratory failure 6 months after PV diagnosis without evidence of pulmonary embolism. The diagnosis of PV in this patient had been made without a BM biopsy but, interestingly, a trephine taken 4 years earlier to investigate pyrexia of unknown origin showed trilineage hyperplasia, small megakaryocyte clusters located close to the trabeculae and mild fibrosis. This is consistent with progression of the MPD to clinically symptomatic disease over a number of years. Patient PV64 presented at 68 years of age with marked erythrocytosis. Interestingly, this patient was thrombocytopenic at presentation and this persisted throughout the course of the disease despite steroid therapy (platelet count varied between 18-119 Â 10 9 l À1 ). Approximately 2 years after presentation, the patient developed marked leukocytosis (WCC 24.0 Â 10 9 l
). A BM biopsy at this time was hypercellular with some dysplastic features, although megakaryocytes were decreased, consistent with the thrombocytopenia seen in this patient. A second BM biopsy, 2 months later (which provided the sample for this study) showed similar findings and with moderate fibrosis reported. The patient progressed to development of acute myeloid leukaemia (AML) within one year and died some months later. Thus, while PV31 and several other patients reported with JAK2 exon 12 mutations are of early onset and generally present with platelet, leukocyte and granulocyte counts within the normal range, 4,5 patients PV63 and PV64 presented with multilineage disease of late onset associated with thrombo-embolic complications (DVT) and rapid transformation to AML, respectively. Furthermore, other modifying factors extrinsic to the haematopoietic system such as coexistent lung disease and chronic inflammation, may be important in the manifestation of disease involving JAK2 exon 12 mutations and, as suggested by Pardanani et al., 5 the specific classification of disease based on alternative JAK2 mutations should be carefully considered as further patients are described. 
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